The document summarizes a clinical trial comparing FOLFIRINOX (folinic acid, fluorouracil, irinotecan, and oxaliplatin) to gemcitabine as first-line treatment for metastatic pancreatic cancer. The trial showed FOLFIRINOX resulted in significantly higher response rates, longer progression-free survival and overall survival, though it also had more grade 3/4 adverse events. Based on these results, the document concludes FOLFIRINOX is a new standard first-line treatment for patients with good performance status.